Light-activatable drugs offer the promise of controlled release with exquisite temporal and spatial resolution. However, light sensitive pro-drugs are typically converted to their active forms using short wavelengths, which display poor tissue penetrance. We report herein erythrocyte-mediated assembly of long wavelength-sensitive phototherapeutics. The activating wavelength of the constructs is readily pre-assigned by using fluorophores with the desired λ ex . Drug release from the erythrocyte carrier was confirmed by standard analytical tools and by the expected biological consequences of the liberated drugs in cell culture: methotrexate, binding to intracellular dihydrofolate reductase; colchicine, inhibition of microtubule polymerization; dexamethasone, induced nuclear migration of the glucocorticoid receptor.
responsible for the intense interest in two-photon [4] and up converting [5] technologies. However, as discussed in recent reviews, [4] [5] both technologies must overcome daunting challenges before potential therapeutic applications are realized. We recently described the long wavelength (>600 nm) photolysis of alkylcobalamins (alkyl-Cbl). [6] We now report the cell-mediated assembly of lipid-Cbl-drug and lipid-fluorophore conjugates in which the latter serve as long wavelength-capturing antennas that promote drug release.
Erythrocytes have been called the "champions of drug delivery" due to their biocompatibility, their long life span (120 days), and their size, which allows large quantities of drug to be conveyed relative to other carriers. [7] However, "practically useful controlled release from carrier RBC (red blood cells) remains an elusive goal". [7] Our strategy to address this issue is depicted in Figure 1 . Based on a previously demonstrated energy transfer between fluorophores and Cbls in covalently appended Cbl-fluorophore conjugates, [6] we decided to explore the premise that the cell-mediated assembly of C 18 -Cbldrug and C 18 -fluorophore conjugates could act in concert as a photo-responsive drug delivery system. Illumination of the fluorophore antenna at its λ max and subsequent energy transfer to the Cbl-drug moiety should result in cleavage of the weak Co-C bond, [6, 8] thereby liberating the drug.
A series of lipidated-Cbl (C 18 -Cbl) and C 18 -fluorophore derivatives were prepared (Figure  2, SI Figures S1-S4, Tables S3-S6 and Scheme S1). In the case of the Cbl derivatives, the C 18 moiety was appended to the 5 ribose -OH of Cbl using octadecylamine and carbonyl-ditriazole. Subsequent alkylation of the Co furnished an amine or carboxylic acid handle, upon which drugs and fluorescent reporters were covalently attached ( Figure 2 , SI Figure S5 and Schemes S2 -S7). These species include the anti-inflammatories methotrexate (MTX), colchicine (COL), and dexamethasone (DEX), and the fluorescent reporters tetramethylrhodamine (TAM) and fluorescein (FAM). The C 18 -fluorophore derivatives were prepared via direct condensation of the activated carboxylate of the fluorophore with the amine of octadecylamine (SI Schemes S8 -S10).
Our initial studies sought to explore the premise of the Figure 1 strategy by establishing light-triggered movement of drugs and reporters from a hydrophobic environment to an aqueous one. For these preliminary experiments we directly photolyzed C 18 -Cbl-drug and C 18 -Cbl-reporter conjugates at the Cbl absorbance wavelength (525 nm). As expected, both C 18 -Cbl-TAM and C 18 -Cbl-MTX are soluble in octanol. Illumination at 525 nm cleaved the C 18 -Cbl-TAM Co-C bond and promoted migration of TAM from octanol to water as assessed by fluorescence (SI Figure S6) . In an analogous fashion, 525 nm illumination of C 18 -Cbl-MTX triggered the release of MTX into the aqueous phase as demonstrated by LC-MS (SI Figure S7) . We subsequently explored the light-triggered transfer of drug/reporter from the lipophilic plasma membrane of erythrocytes to the aqueous milieu. First, exposure of erythrocytes to C 18 -Cbl-TAM revealed even and extensive loading as assessed by widefield fluorescence microscopy. In addition, given the established photolytic sensitivity of the Co-C bond, [6, 8, 9] we were not surprised to find that imaging C 18 -Cbl-TAM on erythrocytes results in the rapid migration (<1 s) of TAM fluorescence from erythrocytes into solution (SI Figure S8 ). Tables S4 -S6 ). Consistent with the established structure activity relationship of MTX derivatives, [10] the photolyzed product of C 18 -Cbl-MTX serves as an effective inhibitor of dihydrofolate reductase (DHFR, SI Figure S11 ). In addition, photo-released MTX from erythrocyteanchored C 18 -Cbl-MTX binds to DHFR in HeLa cells (SI Figure S12) . Tables  S4 -S6 ). The 21-esters of DEX are pro-drugs that are hydrolyzed to DEX in vivo. [11] The possible presence of blood esterases [12] may explain the formation of DEX once freed from the RBC surface. Photo-release of DEX from C 18 -Cbl-DEX-loaded erythrocytes cocultured with HeLa cells results in the migration of glucocorticoid receptor α (GRα) from the cytosol to the nucleus in HeLa cells [SI Figures S15 -S16] . We note that, in the absence of illumination, C 18 -Cbl-MTX-, C 18 -Cbl-COL-, and C 18 -Cbl-DEX-loaded erythrocytes do not release their therapeutic contents (SI Figures S12, S14, S16).
We also examined whether C 18 -Cbl-drugs transfer from erythrocytes to HeLa cells in the absence of light. HeLa cells were incubated with C 18 -Cbl-DEX-loaded erythrocytes and, subsequently, the adherent HeLa cells were washed to remove the red blood cells. If C 18 -Cbl-DEX had migrated to HeLa membranes during the incubation process, illumination at 525 nm should result in DEX release, uptake, and GRα migration. However, we did not observe receptor relocation to the nucleus, suggesting that C 18 -Cbl-DEX is retained by erythrocytes in the dark (SI Figure S17) .
With the biological efficacy of the light triggered release of drugs from erythrocytes established, we turned our attention to the assembly of photo-responsive constructs that (1) operate within the optical window of tissue and (2) are encoded to respond to specific wavelengths. Our choice of anti-inflammatory drugs is based upon their role in the treatment of rheumatoid arthritis (RA). The long-term administration of anti-inflammatory agents produce moderate to severe side effects, such as weight gain, osteoporosis, diabetes mellitus, hypertension, skin fragility and infections arising from being systemically immunocompromised. [13] [14] Not surprisingly, there is significant interest in the development of therapeutics that can be selectively delivered to RA joints. [15] With this in mind, we prepared C 18 derivatives of Cy5 (C 18 -Cy5; λ ex 646 nm), Alexa Fluor 700 (C 18 -AF700; λ ex 700 nm), Cy7 (C 18 -Cy7; λ ex 747 nm), and a DyLight 800 analog (C 18 -DY800; λ ex 784 nm) and examined whether they are capable of serving as long wavelength antennas for drug release. Photolysis experiments employed in-house constructed LED circuit boards centered at 660 nm (Cy5), 725 nm (AF700 and Cy7), and 780 nm (DY800) (SI Figure S18 and Table S7 ).
Our initial studies employed C 18 -Cbl-TAM in the presence of the C 18 -fluorophores, since the photo-release of TAM from C 18 -Cbl-TAM-labelled erythrocytes is readily monitored by fluorescence. In order to identify optimal energy transfer conditions, we first exposed erythrocytes to various relative concentrations of C 18 -Cbl-TAM and C 18 -Cy5. After washing the erythrocytes to remove any unbound C 18 -Cbl-TAM and C 18 -Cy5, the loaded RBCs were illuminated at 660 nm. The carrier erythrocytes were subsequently pelleted via centrifugation and TAM fluorescence in the supernatant measured. Although the most efficient TAM release was observed with erythrocytes exposed to a 1 µM:10 µM of C 18 -Cbl-TAM:C 18 -Cy5 (SI Figure S19 ), we employed a 1 µM:5 µM ratio to keep disruption of the erythrocyte's structural integrity at an absolute minimum. In addition to the C 18 -Cy5 @ 660 nm antenna, the photo-release of TAM from C 18 -Cbl-TAM-loaded erythrocytes can be triggered at longer wavelengths in the presence of other antennas [C 18 -Cy7 @ 725 nm, C 18 -Cy7 @ 725 nm, C 18 -DY800 @780 nm]. Figure 4 compares the fraction of TAM released as a function of (a) antenna wavelength, (b) power of the different LEDs, and (c) photon density. An analogous set of experiments with similar results was performed with C 18 -Cbl-FAM/C 18 -fluorophores (SI Figure S20) . Erythrocytes in the dark do not release TAM or FAM and, erythrocytes lacking a fluorophore antenna do not release FAM or TAM at wavelengths longer than those absorbed by Cbl (SI Figures S21 -S23) . Finally, confocal microscopy revealed that the structural integrity of erythrocytes is not altered by the addition of the C 18 -fluorophores (SI Figure S24) .
We subsequently examined drug photo-release from the erythrocyte-assembled drug/antenna array. C 18 -Cbl-MTX, C 18 -Cbl-COL, and C 18 -Cbl-DEX were each paired with C 18 -fluorophores and illuminated. LC-MS confirmed the release of MTX, COL, and DEX at the wavelength absorbed by the partner C 18 -fluorophore (SI Figures S25 -S26 and Table S8 ):
C 18 -Cbl-DEX/C 18 -Cy5: DEX is released from C 18 -Cbl-DEX/C 18 -Cy5-loaded erythrocytes in culture with HeLa cells upon 660 nm exposure. As a consequence, GRα in HeLa cells migrates from the cytoplasm to the nucleus (Figure 5a-b) . By contrast, C 18 -Cbl-DEX loaded erythrocytes lacking a long wavelength absorbing antenna fail to trigger GRα migration when exposed to long wavelengths (e.g. 780 nm; SI Figures S27 -S28 ).
C 18 -Cbl-COL/C 18 -DY800: 780 nm elicits COL release from erythrocyte-anchored C 18 -Cbl-COL/C 18 -DY800, which induces microtubule depolymerization in the plated HeLa cells (Figure 5c-d, SI Figure S29 ).
C 18 -Cbl-MTX/C 18 -Cy7: MTX is released from C 18 -Cbl-MTX/C 18 -Cy7-loaded erythrocytes upon 725 nm exposure. The MTX photo-product associates with endogenous DHFR in the co-cultured HeLa cells as assessed by the cellular thermal shift assay (Figure 5e ). [16] In summary, we've described the cell-mediated assembly of photo-responsive drug release constructs. Release is triggered upon exposure to far-red and near-IR light that falls well within the optical window of tissue. Furthermore, drug release is wavelength-encodable; enabling the action wavelength to be chosen in advance based upon the known excitation properties of a given fluorophore. Finally, although this study focused on erythrocytes as drug carriers, the strategy described herein should prove applicable to nanoparticle drug carriers as well. [17] 
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